Contact – +1-276-477-5910
 Email – [email protected]

Home >>

China Outlook 2023

>>

The - Outlook for Biosimilars and Follow-on Biologics Drugs in China

The 2023-2028 Outlook for Biosimilars and Follow-on Biologics Drugs in China
Report code: SDMRCH1645998 | Industry: China Outlook 2023 | Published On: 8/16/2022
 Sample & Brochure   Talk to Analyst   Request Customization  Make an enquiry   Discount

This study covers the latent demand outlook for biosimilars and follow-on biologics drugs across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biosimilars and follow-on biologics drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of biosimilars and follow-on biologics drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Allozyne, Alteogen, Alvogen, Amarey Novamedical, AMEGA Biotech, Amgen, Apotex, Astellas Pharma, AstraZeneca, Avesthagen, Baxter, Bayer, Beijing Four Rings, BIOCAD, Bioceuticals, Biocon, Biogen, Biolab, Bionovis, Biopartners, Biosidus, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Cambridge Antibody Technology, CCL Pharmaceuticals, CCM Duopharma, Celltrion, Centocor Ortho Biotech, Chong Kun Dang, Chugai, CinnaGen., Coherus BioSciences, Compass Biotechnologies, Cristália, CT Arzneimittel, Cyplasin, Daiichi Sankyo, Dong-A Pharmaceutical, Dr. Reddy’s Laboratories, Egis Pharmaceuticals, Eisai, Eli Lilly, Elpen Pharmaceutical, Emcure Pharmaceuticals, EMS, Epirus, Eurofarma, Express Scripts, FibroGen, Finox Biotech, Fuji Pharma, Gan & Lee, Genetech, Genexine, Gennova, GenSci, Genzyme, Geropharm, Gilead Sciences, GlaxoSmithKline, Hangzhou Jiuyuan Gene Engineering Company, Hanmi Pharmaceutical, Hanwha Chemical, Haselmeier, Health Canada, Helius Biotech, Hexal, Hindustan Antibiotic, Hospira, Hualida Biotech, Hypermarcas, IGES Institute, Intas Biopharmaceuticals, inVentiv Health, JCR Pharmaceuticals, Johnson & Johnson, Kabi, Kemwell Biopharma, Kissea, Koçak Farma, Kwizda Pharma, Kyowa Hakko Kirin, Landsteiner Scientific, LG Life Sciences, Libbs, LKM SA, Lonza Group, Mabion, Marvel Life Sciences, MEDICE Arzneimittel Pütter, Merck (MSD), Minapharm, Mitsubishi Tanabe, Mochida Pharmaceutical, Momenta Pharmaceuticals, Mycenax Biotech, Mylan, Nichi-Iko, Nippion Kayaku, Novartis, Novo Nordisk, Nuron Biotech, Oncobiologics, Ortho Pharmaceutical, Orygen, PanGen Biotech, Pfenex, Pfizer, Pharmapark, Pharmstandard, PRA International, Pro Generika, Qilu Pharmaceutical, Quintiles, Ranbaxy Laboratories, RAND Corporation, Ratiopharm, Regeneron Pharmaceuticals, Reliance GeneMedix, Rentschler Biotechnologie, Roche, Samsung Bioepis, Sandoz, Sanofi, SciGen, Shandong Kexing Pharma, Shanghai Celgen Biopharmaceutical, Shantha Biotechnics, Shinogi, Sicor Biotech, Sothema Laboratories, Spectrum Pharmaceuticals, Stada Arzneimittel, Stragen Pharma, Strides Arcolab, Syngene International, Synthon Biopharmaceuticals, Takeda, Teva, Tianjin Hualida Biotechnology, Tonghua Dongbao, TSH Biopharm, União Química, USV Biologics, Virchow Biotech, Wanbang Biopharmaceuticals, Wockhardt, Xiamen Amoytop Biotech, Zenotech, Zhejian Huahai Pharmaceutical, Zuventus, and Zydus Biovation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

1 INTRODUCTION
1.1 OVERVIEW
1.2 WHAT  IS  LATENT  DEMAND  AND  THE  P.I.E.?
1.3 THE  METHODOLOGY
1.3.1 STEP  1.  PRODUCT  DEFINITION  AND  DATA  COLLECTION
1.3.2 STEP  2.  FILTERING  AND  SMOOTHING
1.3.3 STEP  3.  FILLING  IN  MISSING  VALUES
1.3.4 STEP  4.  VARYING  PARAMETER,  NON-LINEAR  ESTIMATION
1.3.5 STEP  5.  FIXED-PARAMETER  LINEAR  ESTIMATION
1.3.6 STEP  6.  AGGREGATION  AND  BENCHMARKING
1.4 FREQUENTLY  ASKED  QUESTIONS  (FAQ)
1.4.1 CATEGORY  DEFINITION
1.4.2 UNITS
1.4.3 METHODOLOGY
2 SUMMARY  OF  FINDINGS
2.1 LATENT  DEMAND  IN  CHINA
2.2 TOP  100  CITIES  SORTED  BY  RANK
2.3 LATENT  DEMAND  BY  YEAR  IN  CHINA
3 ANHUI
3.1 LATENT  DEMAND  BY  YEAR  -  ANHUI
3.2 CITIES  SORTED  BY  RANK  -  ANHUI
3.3 CITIES  SORTED  ALPHABETICALLY  -  ANHUI
4 BEIJING
4.1 LATENT  DEMAND  BY  YEAR  -  BEIJING
4.2 CITIES  SORTED  BY  RANK  -  BEIJING
4.3 CITIES  SORTED  ALPHABETICALLY  -  BEIJING
5 CHONGQING
5.1 LATENT  DEMAND  BY  YEAR  -  CHONGQING
5.2 CITIES  SORTED  BY  RANK  -  CHONGQING
5.3 CITIES  SORTED  ALPHABETICALLY  -  CHONGQING
6 FUJIAN
6.1 LATENT  DEMAND  BY  YEAR  -  FUJIAN
6.2 CITIES  SORTED  BY  RANK  -  FUJIAN
6.3 CITIES  SORTED  ALPHABETICALLY  -  FUJIAN
7 GANSU
7.1 LATENT  DEMAND  BY  YEAR  -  GANSU
7.2 CITIES  SORTED  BY  RANK  -  GANSU
7.3 CITIES  SORTED  ALPHABETICALLY  -  GANSU
8 GUANGDONG
8.1 LATENT  DEMAND  BY  YEAR  -  GUANGDONG
8.2 CITIES  SORTED  BY  RANK  -  GUANGDONG
8.3 CITIES  SORTED  ALPHABETICALLY  -  GUANGDONG
9 GUANGXI
9.1 LATENT  DEMAND  BY  YEAR  -  GUANGXI
9.2 CITIES  SORTED  BY  RANK  -  GUANGXI
9.3 CITIES  SORTED  ALPHABETICALLY  -  GUANGXI
10 GUIZHOU
10.1 LATENT  DEMAND  BY  YEAR  -  GUIZHOU
10.2 CITIES  SORTED  BY  RANK  -  GUIZHOU
10.3 CITIES  SORTED  ALPHABETICALLY  -  GUIZHOU
11 HAINAN
11.1 LATENT  DEMAND  BY  YEAR  -  HAINAN
11.2 CITIES  SORTED  BY  RANK  -  HAINAN
11.3 CITIES  SORTED  ALPHABETICALLY  -  HAINAN
12 HEBEI
12.1 LATENT  DEMAND  BY  YEAR  -  HEBEI
12.2 CITIES  SORTED  BY  RANK  -  HEBEI
12.3 CITIES  SORTED  ALPHABETICALLY  -  HEBEI
13 HEILONGJIANG
13.1 LATENT  DEMAND  BY  YEAR  -  HEILONGJIANG
13.2 CITIES  SORTED  BY  RANK  -  HEILONGJIANG
13.3 CITIES  SORTED  ALPHABETICALLY  -  HEILONGJIANG
14 HENAN
14.1 LATENT  DEMAND  BY  YEAR  -  HENAN
14.2 CITIES  SORTED  BY  RANK  -  HENAN
14.3 CITIES  SORTED  ALPHABETICALLY  -  HENAN
15 HONG  KONG
15.1 LATENT  DEMAND  BY  YEAR  -  HONG  KONG
15.2 CITIES  SORTED  BY  RANK  -  HONG  KONG
15.3 CITIES  SORTED  ALPHABETICALLY  -  HONG  KONG
16 HUBEI
16.1 LATENT  DEMAND  BY  YEAR  -  HUBEI
16.2 CITIES  SORTED  BY  RANK  -  HUBEI
16.3 CITIES  SORTED  ALPHABETICALLY  -  HUBEI
17 HUNAN
17.1 LATENT  DEMAND  BY  YEAR  -  HUNAN
17.2 CITIES  SORTED  BY  RANK  -  HUNAN
17.3 CITIES  SORTED  ALPHABETICALLY  -  HUNAN
18 JIANGSU
18.1 LATENT  DEMAND  BY  YEAR  -  JIANGSU
18.2 CITIES  SORTED  BY  RANK  -  JIANGSU
18.3 CITIES  SORTED  ALPHABETICALLY  -  JIANGSU
19 JIANGXI
19.1 LATENT  DEMAND  BY  YEAR  -  JIANGXI
19.2 CITIES  SORTED  BY  RANK  -  JIANGXI
19.3 CITIES  SORTED  ALPHABETICALLY  -  JIANGXI
20 JILIN
20.1 LATENT  DEMAND  BY  YEAR  -  JILIN
20.2 CITIES  SORTED  BY  RANK  -  JILIN
20.3 CITIES  SORTED  ALPHABETICALLY  -  JILIN
21 LIAONING
21.1 LATENT  DEMAND  BY  YEAR  -  LIAONING
21.2 CITIES  SORTED  BY  RANK  -  LIAONING
21.3 CITIES  SORTED  ALPHABETICALLY  -  LIAONING
22 MACAU
22.1 LATENT  DEMAND  BY  YEAR  -  MACAU
22.2 CITIES  SORTED  BY  RANK  -  MACAU
22.3 CITIES  SORTED  ALPHABETICALLY  -  MACAU
23 NEI  MONGGOL
23.1 LATENT  DEMAND  BY  YEAR  -  NEI  MONGGOL
23.2 CITIES  SORTED  BY  RANK  -  NEI  MONGGOL
23.3 CITIES  SORTED  ALPHABETICALLY  -  NEI  MONGGOL
24 NINGXIA
24.1 LATENT  DEMAND  BY  YEAR  -  NINGXIA
24.2 CITIES  SORTED  BY  RANK  -  NINGXIA
24.3 CITIES  SORTED  ALPHABETICALLY  -  NINGXIA
25 QINGHAI
25.1 LATENT  DEMAND  BY  YEAR  -  QINGHAI
25.2 CITIES  SORTED  BY  RANK  -  QINGHAI
25.3 CITIES  SORTED  ALPHABETICALLY  -  QINGHAI
26 SHAANXI
26.1 LATENT  DEMAND  BY  YEAR  -  SHAANXI
26.2 CITIES  SORTED  BY  RANK  -  SHAANXI
26.3 CITIES  SORTED  ALPHABETICALLY  -  SHAANXI
27 SHANDONG
27.1 LATENT  DEMAND  BY  YEAR  -  SHANDONG
27.2 CITIES  SORTED  BY  RANK  -  SHANDONG
27.3 CITIES  SORTED  ALPHABETICALLY  -  SHANDONG
28 SHANGHAI
28.1 LATENT  DEMAND  BY  YEAR  -  SHANGHAI
28.2 CITIES  SORTED  BY  RANK  -  SHANGHAI
28.3 CITIES  SORTED  ALPHABETICALLY  -  SHANGHAI
29 SHANXI
29.1 LATENT  DEMAND  BY  YEAR  -  SHANXI
29.2 CITIES  SORTED  BY  RANK  -  SHANXI
29.3 CITIES  SORTED  ALPHABETICALLY  -  SHANXI
30 SICHUAN
30.1 LATENT  DEMAND  BY  YEAR  -  SICHUAN
30.2 CITIES  SORTED  BY  RANK  -  SICHUAN
30.3 CITIES  SORTED  ALPHABETICALLY  -  SICHUAN
31 TAIWAN
31.1 LATENT  DEMAND  BY  YEAR  -  TAIWAN
31.2 CITIES  SORTED  BY  RANK  -  TAIWAN
31.3 CITIES  SORTED  ALPHABETICALLY  -  TAIWAN
32 TIANJIN
32.1 LATENT  DEMAND  BY  YEAR  -  TIANJIN
32.2 CITIES  SORTED  BY  RANK  -  TIANJIN
32.3 CITIES  SORTED  ALPHABETICALLY  -  TIANJIN
33 XINJIANG  UYGUR
33.1 LATENT  DEMAND  BY  YEAR  -  XINJIANG  UYGUR
33.2 CITIES  SORTED  BY  RANK  -  XINJIANG  UYGUR
33.3 CITIES  SORTED  ALPHABETICALLY  -  XINJIANG  UYGUR
34 XIZANG  [TIBET]
34.1 LATENT  DEMAND  BY  YEAR  -  XIZANG  [TIBET]
34.2 CITIES  SORTED  BY  RANK  -  XIZANG  [TIBET]
34.3 CITIES  SORTED  ALPHABETICALLY  -  XIZANG  [TIBET]
35 YUNNAN
35.1 LATENT  DEMAND  BY  YEAR  -  YUNNAN
35.2 CITIES  SORTED  BY  RANK  -  YUNNAN
35.3 CITIES  SORTED  ALPHABETICALLY  -  YUNNAN
36 ZHEJIANG
36.1 LATENT  DEMAND  BY  YEAR  -  ZHEJIANG
36.2 CITIES  SORTED  BY  RANK  -  ZHEJIANG
36.3 CITIES  SORTED  ALPHABETICALLY  -  ZHEJIANG
37 DISCLAIMERS,  WARRANTIES,  AND  USER  AGREEMENT  PROVISIONS
37.1 DISCLAIMERS  &  SAFE  HARBOR
37.2 ICON  GROUP  INTERNATIONAL,  INC.  USER  AGREEMENT  PROVISIONS
To know more kindly contact, [email protected]
 Feel free to contact us

 
Choose License Type
Select User Type


Report code


Buy Now

x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT